Announced details
Curative treatment of dystrophic epidermolysis bullosa
We have been conducting research and development on regenerative medicine products with Osaka University under the name "Regenerative Inductive Medicine®." The applicant for the patent is National University Corporation Osaka University.
Registration number: To be assigned. Application number: 10-2023-7005854
There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly.
The company does not address Contract Value / Offering price.
Japan Agency for Medical Research and Development (AMED)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Stem cell gene therapy technology (Development Code: SR-GT1) |
| Counterparty | Osaka University National University Corporation |
| Relationship with the Company | We have been conducting research and development on regenerative medicine products with Osaka University under the name "Regenerative Inductive Medicine®." The applicant for the patent is National University Corporation Osaka University. |
| Applicable area | Curative treatment of dystrophic epidermolysis bullosa |
| Registration number and expiry date | Registration number: To be assigned. Application number: 10-2023-7005854 |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2026. Any material matter requiring disclosure will be disclosed promptly. |
| Source | Japan Agency for Medical Research and Development (AMED) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The patent for therapeutic cells related to SR-GT1, which we are developing, is to be registered in Korea.